Cargando…

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis

BACKGROUND: Checkpoint inhibitor pneumonitis (CIP) that does not respond to corticosteroids is termed steroid-refractory CIP. We aimed to find risk factors of steroid-refractory CIP and evaluate the management strategies of immunomodulators (IMs). METHODS: Patients with CIP were identified between A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yanlin, Jia, Xiaohui, Zhang, Yajuan, Du, Yonghao, Chang, Yuzhu, Shen, Yuan, Mao, Ziyang, Liu, Mengjie, Sun, Hong, Guo, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254972/ https://www.ncbi.nlm.nih.gov/pubmed/37290926 http://dx.doi.org/10.1136/jitc-2023-006982

Ejemplares similares

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
por: Franken, Amelie, et al.
Publicado: (2022)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
por: Alexander, James L, et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Reid, Pankti, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
por: Du, Yang, et al.
Publicado: (2022)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
por: Kelleher, Thomas, et al.
Publicado: (2021)

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
por: Alexander, James L, et al.
Publicado: (2022)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
por: Ahmed, Murtaza, et al.
Publicado: (2021)

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
por: Gupta, Shruti, et al.
Publicado: (2022)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
por: Storkus, Walter J, et al.
Publicado: (2021)

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
por: Meraz-Muñoz, Alejandro, et al.
Publicado: (2020)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
por: Sussman, Tamara A, et al.
Publicado: (2021)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Bae, Seongman, et al.
Publicado: (2021)

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
por: Puzanov, Igor, et al.
Publicado: (2021)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease
por: Bender, David Andrew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_okct4nqkn02m186nnpb0jt5dn8